NCT06869434View on ClinicalTrials.gov

Thoraco Lumbar Vertebral Length and Bupivacaine Dosage in C-Section

NARecruitingINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

May 1, 2026

Conditions
Obstetric Anesthesia ProblemsBupivacaine Adverse Reaction
Interventions
PROCEDURE

Group VBL (Thoracolumbal vertebral body length) received 0.2 mg x VBL cm of %0.5 hyperbaric bupivacaine

intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight. A dosage was derived using Harten's dose chart formulated for Caucasian parturients

PROCEDURE

Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm

Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm

PROCEDURE

Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.

Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.

Trial Locations (1)

38050

RECRUITING

Kudret Doğru, Kayseri

All Listed Sponsors
lead

TC Erciyes University

OTHER